| 000 | 01507 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250514015144.0 | ||
| 264 | 0 | _c20020917 | |
| 008 | 200209s 0 0 eng d | ||
| 022 | _a1042-8194 | ||
| 024 | 7 |
_a10.3109/10428190109099335 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHarjunpää, A | |
| 245 | 0 | 0 |
_aComplement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cAug 2001 |
||
| 300 |
_a731-8 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aBlood Circulation _ximmunology |
| 650 | 0 | 4 | _aBlood-Brain Barrier |
| 650 | 0 | 4 |
_aCentral Nervous System _ximmunology |
| 650 | 0 | 4 |
_aCerebrospinal Fluid _xchemistry |
| 650 | 0 | 4 |
_aComplement Activation _xdrug effects |
| 650 | 0 | 4 |
_aComplement C3a _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xcerebrospinal fluid |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRituximab |
| 700 | 1 | _aWiklund, T | |
| 700 | 1 | _aCollan, J | |
| 700 | 1 | _aJanes, R | |
| 700 | 1 | _aRosenberg, J | |
| 700 | 1 | _aLee, D | |
| 700 | 1 | _aGrillo-López, A | |
| 700 | 1 | _aMeri, S | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 42 _gno. 4 _gp. 731-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428190109099335 _zAvailable from publisher's website |
| 999 |
_c11612995 _d11612995 |
||